The University of Chicago Header Logo

Connection

Arlene Chapman to Biomarkers

Back to Details
This is a "connection" page, showing publications Arlene Chapman has written about Biomarkers.
Arlene Chapman
Connection Strength
0.799
Biomarkers
  1. Hypoxia-Inducible Factor 1a (HIF-1a), Angiopoietin-2 (ANG-2) and Endocan: Novel Biomarkers of Disease Progression Involving Polycystic Kidney Disease. Am J Nephrol. 2018; 47(4):228-230.
    View in: PubMed
    Score: 0.102
  2. Whole Transcriptome Sequencing Analyses Reveal Molecular Markers of Blood Pressure Response to Thiazide Diuretics. Sci Rep. 2017 11 22; 7(1):16068.
    View in: PubMed
    Score: 0.099
  3. New treatment paradigms for ADPKD: moving towards precision medicine. Nat Rev Nephrol. 2017 Dec; 13(12):750-768.
    View in: PubMed
    Score: 0.098
  4. Urinary proteomic biomarkers for diagnosis and risk stratification of autosomal dominant polycystic kidney disease: a multicentric study. PLoS One. 2013; 8(1):e53016.
    View in: PubMed
    Score: 0.071
  5. Evaluation of urine biomarkers of kidney injury in polycystic kidney disease. Kidney Int. 2012 Apr; 81(8):784-90.
    View in: PubMed
    Score: 0.066
  6. Predictors of blood pressure response to the angiotensin receptor blocker candesartan in essential hypertension. Am J Hypertens. 2008 Jan; 21(1):61-6.
    View in: PubMed
    Score: 0.050
  7. Circulating microRNA Biomarkers of Thiazide Response in Hypertension. J Am Heart Assoc. 2024 Feb 20; 13(4):e032433.
    View in: PubMed
    Score: 0.038
  8. Utility of new image-derived biomarkers for autosomal dominant polycystic kidney disease prognosis using automated instance cyst segmentation. Kidney Int. 2023 08; 104(2):334-342.
    View in: PubMed
    Score: 0.036
  9. Utilization of Cystatin C in the Outpatient Setting. Am J Nephrol. 2022; 53(7):534-541.
    View in: PubMed
    Score: 0.034
  10. Response to: Heterogeneous Treatment Response by Race Cannot Be Claimed in the Absence of Evidence. Am J Hypertens. 2020 02 22; 33(2):e2.
    View in: PubMed
    Score: 0.029
  11. Plasma Renin Activity Is a Predictive Biomarker of Blood Pressure Response in European but not in African Americans With Uncomplicated Hypertension. Am J Hypertens. 2019 06 11; 32(7):668-675.
    View in: PubMed
    Score: 0.028
  12. Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease. Kidney Int. 2019 07; 96(1):159-169.
    View in: PubMed
    Score: 0.027
  13. Genome Wide Association Study Identifies the HMGCS2 Locus to be Associated With Chlorthalidone Induced Glucose Increase in Hypertensive Patients. J Am Heart Assoc. 2018 03 09; 7(6).
    View in: PubMed
    Score: 0.025
  14. Fibroblast Growth Factor 23 and Kidney Disease Progression in Autosomal Dominant Polycystic Kidney Disease. Clin J Am Soc Nephrol. 2017 Sep 07; 12(9):1461-1469.
    View in: PubMed
    Score: 0.024
  15. Tolvaptan suppresses monocyte chemotactic protein-1 excretion in autosomal-dominant polycystic kidney disease. Nephrol Dial Transplant. 2017 Jun 01; 32(6):969-975.
    View in: PubMed
    Score: 0.024
  16. Image texture features predict renal function decline in patients with autosomal dominant polycystic kidney disease. Kidney Int. 2017 11; 92(5):1206-1216.
    View in: PubMed
    Score: 0.024
  17. Urine peptidome analysis predicts risk of end-stage renal disease and reveals proteolytic pathways involved in autosomal dominant polycystic kidney disease progression. Nephrol Dial Transplant. 2017 03 01; 32(3):487-497.
    View in: PubMed
    Score: 0.024
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.